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Abstract Rationale: Exposure to extreme stress has been
suggested to produce long-term, detrimental alterations in
the hypothalamic–pituitary–adrenal (HPA) axis leading to
the development of mental disorders such as depression.
Therefore, compounds that block the effects of stress hor-
mones were investigated as potential therapeutics for de-
pression. Objectives: In the present study, we compared
the potential antidepressant-like effects of four CRF antag-
onists, antalarmin, CP154,526, R121919, and LWH234 (at
3, 10, and 30 mg/kg i.p., 60 min prior to the forced swim
test) and the corresponding effect on swim-induced HPA
activation to better elucidate the relation between HPA
activity and antidepressant activity. Methods: The antide-
pressant-like effects of the CRF antagonists and known
antidepressants were determined in the rat forced swim test,
and blood samples were obtained before and after swim-
ming for the evaluation of adrenocorticotropin-releasing
hormone (ACTH) levels. Results: Antalarmin, CP154,526,
and R121919 did not produce antidepressant-like effects in
the forced swim test although these compounds decreased
swim-induced increases in ACTH to various extents. In
contrast, LWH234 reduced immobility in the forced swim
test, without altering the swim-stress-induced ACTH re-
sponse. However, this compound antagonized restraint-in-
ducedACTH release. Conclusions: These data suggest that
reducing stress-induced increases in HPA activity alone
may not be sufficient to produce antidepressant-like ac-
tivity; however, reductions in HPA activity may contribute
to antidepressant actions of some treatments. In addition, it
is proposed that CRF antagonists may alter differentially the
HPA axis depending on the type of stressor used or be-
havioral measure evaluated.
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Introduction
Following acute exposure to a stressful event, the hy-
pothalamic–pituitary–adrenal (HPA) axis is activated, re-
leasing stress hormones into circulation that alter many
physiological and behavioral processes. More specifically,
cells in the paraventricular nucleus of the hypothalamus
secrete corticotropic-releasing factor (CRF) into portal blood,
activating CRF receptors in the pituitary and causing the
release of adrenocorticotropin-releasing hormone (ACTH)
into the bloodstream. ACTH acts at the adrenal glands to
release glucocorticoids, cortisol (in humans and primates)
or corticosterone (in rodents). Circulating glucocorticoids
can act in the brain and at the pituitary to dampen HPA axis
activation, termed negative feedback. These stress re-
sponses are required for fight-and-flight responses that are
essential for survival. Many current theories suggest that, in
some individuals, continued exposure to extreme stress
produces detrimental alterations in the HPA axis participat-
ing in the development of mental disorders such as anxiety
and depression (e.g., Holsboer 1999, 2000; McEwen 2000).
In clinical studies, it has been observed that some de-
pressed patients demonstrate a hyperactivity of the HPA
axis as well as an impaired negative feedback system (for
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review, see Holsboer and Barden 1996). However, this hy-
peractivity, although not observed in all patients with de-
pression (Watson et al. 2002), has been identified as a useful
diagnostic tool. It has been suggested that a successful
treatment with a variety of antidepressant medications and
therapies reverses HPA hyperactivity. For example, in
depressed patients, fluoxetine reduced CRF in the CSF and
improved the depression scores on the Hamilton Depres-
sion Rating Scale (De Bellis et al. 1993). Therefore, poten-
tial therapeutics that selectively block the HPA axis may
prove useful as novel antidepressant treatments. To inves-
tigate the potential therapeutic effect of CRF antagonists, a
preliminary study with the CRF receptor 1 (CRF-R1) antag-
onist R121919 in 20 depressed patients demonstrated that
R121919 reduced depression scores; however, in these pa-
tients, it did not block HPA activity following CRF chal-
lenge (Zobel et al. 2000).
The use of CRF receptor 1 (CRF-R1) antagonists as
potential antidepressant therapies has been studied in
animal models. The CRF-R1 antagonist CP154,526 dem-
onstrated antidepressant-like effects in the learned help-
lessness model of depression (Mansbach et al. 1997). Also,
the CRF-R1 antagonists antalarmin and SSR125543A
decreased the duration of immobility in the forced swim
test in rats, indicating an antidepressant-like effect with
these compounds (Griebel et al. 2002a). Conversely, HPA
activity was elevated in a number of animal strains that have
inherent depressive-like behaviors and are used as models
of depression (Rittenhouse et al. 2002; Urani and Gass
2003; Keck et al. 2003).
Although CRF antagonists produced antidepressant-like
effects in some studies, few reports directly compared anti-
depressant activity with the effects on the HPA axis within
the same experimental conditions. Some previous studies
demonstrated that CRH antagonists might not antagonize
stress-induced endocrinological changes in a similar man-
ner (Deak et al. 1999; Broadbear et al. 2004). Therefore, in
the present study we compared the potential antidepressant-
like effects of four CRF antagonists and the corresponding
effect on swim-induced HPA activation to better elucidate
the relation between HPA activity and antidepressant ac-
tivity. Four CRF antagonists, antalarmin, LWH234, CP154,526,
and R121919 (Fig. 1), are compared with two known
antidepressants, desipramine and fluoxetine, in the forced
swim test in rats. In addition, the blood serum levels of rats
exposed to the forced swim test were tested for levels of
ACTH to determine if behavioral changes correlated with
inhibition of swim-induced increases in ACTH. Based on
previous findings, it was hypothesized that all of the CRF
antagonists tested would have similar effects on swim-
induced increases in ACTH and similar antidepressant
properties, as measured in the forced swim test in Sprague–
Dawley rats. In the current studies, antalarmin, CP154,526,
and R121919 did not produce antidepressant-like effects
in the forced swim test although these compounds reduced
swim-induced increases inACTH to different extents. How-
ever, the CRF antagonist LWH234 significantly decreased
immobility in the forced swim test without reducing the
HPA axis response. In general, these data suggest that al-
tering HPA activity alone through CRF-R1 receptor occu-
pation may not be sufficient to produce antidepressant
effects.
Materials and methods
Subjects Male Sprague–Dawley rats, weighing 250–300 g,
were used in these studies (Harlan Sprague Dawley,
Indianapolis, IN). Upon arrival, groups of three rats were
housed in clear acrylic cages located in a climate-controlled
room with 12-h light/dark cycle (lights on at 0600). Food
and water were available ad libitum. Rats were allowed to
habituate to the environment for at least 5 days before they
were used for study. In forced swim test experiments, rats
were randomly assigned to either vehicle or drug treatment
groups. In restraint experiments, rats were singly housed for
7 days after the initial acclimation period before testing
commenced. Studies were performed in accordance with
Fig. 1 Structures of antalarmin (a), LWH234 (b), CP154,526 (c),
and R121919 (d)
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the Declaration of Helsinki and with the Guide for the Care
and Use of Laboratory Animals as adopted and promul-
gated by the National Institutes of Health. The experimental
protocols were approved by the University of Michigan
University Committee on the Use and Care of Animals.
Procedures
Blood sampling Rat blood samples were collected from a
nick at the tip of tail. Without restraining the rat, the tail
was gently massaged to increase blood collection. For
each sample, 240 μl of blood was collected in heparinized
microhematocrit capillary tubes (Fisher Scientific, Chicago,
IL). Blood samples were stored on ice (less than 15 min)
until centrifuged (4,100 rpm), and blood plasma was re-
moved and stored at −80°C. Blood samples were collected
between 1300 and 1700 h.
Forced swim test Rats swam in a clear acrylic container
[46 cm (height)×20 cm (diameter)] filled with 30 cm of
25°C (±1°C) water. Two swimming sessions were con-
ducted: one 15-min swim exposure (habituation, day 1),
followed by a 5-min swim 24 h later (test, day 2). The 5-min
test swim was videotaped from above the cylinder and
scored at a later time. Cylinder water was changed after
every other rat. After each swim period, the rats were re-
moved from the water, towel-dried, and placed in a heated
cage for 15 min. Rat tail blood samples were taken imme-
diately before and after each swim session.
Videotaped 5-min test swims were scored for immobility,
swimming, and climbing behaviors (Detke et al. 1995).
These behaviors are defined as follows: immobility—
floating in the water without struggling and using only
small movements to keep the head above water; swimming
—moving limbs in an active manner (more than required to
keep head above water) causing movement around the
cylinder; climbing—making active movements with the
forepaws in and out of the water, usually directed against
the wall. Every 5 s, a trained observer who was blind to the
treatment conditions categorized the subject’s behavior as
one of the three behaviors listed previously. The total
counts of each behavior during the 5-min test swim were
summed for each rat and averaged within each treatment
group.
Restraint Baseline blood samples were obtained from each
rat as previously described prior to drug injection. Fol-
lowing baseline blood collection, rats were injected with
either vehicle or drug (time 0). Sixty minutes after the
injection, rats were placed headfirst into 8.57×21.59-cm
clear plastic cylinders (Braintree Scientific, Braintree, MA)
for 15 min. The restraint cylinder allowed limited move-
ment of the head and limbs; however, the tail was exposed
to allow for easy blood collection. Blood samples were then
collected at 15, 30, 60, 90 min after restraint initiation (75,
90, 120, 180, 240 min post injection). Between blood
collections, rats were returned to their home cage.
ACTH measurements Blood plasma samples were assayed
using radioimmunoassay kits for adrenocorticotropin (ACTH;
Nichols Institute Diagnostics, San Juan Capistrano, CA).
The ACTH assay kit measures the amount of intact ACTH
molecules that contain both N-terminal and C-terminal
regions, and the assay has a sensitivity of 1.0 pg/ml. In these
experiments, only ACTH was measured because the time
points of blood collection were not optimal for measuring
corticosterone levels in blood plasma. Blood samples were
collected immediately before and after swim (either 5 or
15 min after swim exposure) at time points prior to maximal
corticosterone release.
Drug treatments
In the forced swim test, drugs were administered three times
prior to day 2 swim, such that intraperitoneal (i.p.) in-
jections were administered 23.5, 5, and 1 h prior to the
5-min swim test. Rats (N=6–8 per treatment) were ad-
ministered three injections of the same dose of either de-
sipramine (1, 3, or 10mg/kg), fluoxetine (1, 3, or 10mg/kg),
antalarmin (3, 10, or 30 mg/kg), CP154,526 (3, 10, or
30 mg/kg), LWH234 (3, 10, or 30 mg/kg), R121919 (3, 10,
or 30 mg/kg), or vehicle. Desipramine and fluoxetine were
dissolved in sterile saline. Antalarmin, CP154,526, and
LWH234 were dissolved in a 1:1:9 solution of ethanol,
emulphor (oil), and sterile water, respectively. R121919
was dissolved in ∼10% of a 0.1 M tartaric acid solution and
90% sterile water. Vehicle injections consisted of the
appropriate solvent. In the restraint experiment, rats (N=6)
were administered a single injection (i.p.) of either vehicle,
10, or 30 mg/kg LWH234 60 min before restraint initiation.
Injection volumes were 1 to 1.5 ml/kg.
Statistical analysis
Each behavior in the forced swim test was compared among
groups by using a one-way factorial analysis of variance
(ANOVA). Dunnett’s post hoc comparison was used to
compare control vehicle groups to groups treated with
drugs. ACTH values for post 5-min swim were compared
using one-way factorial analysis and Dunnett’s post hoc
comparisons were used to determine statistical significant
differences between treatment groups.
Results
Forced swim test Immobility scores associated with ad-
ministration of the vehicle solution were relatively high
between 33 and 39 counts (Fig. 2). Swimming and climbing
scores were low in rats treated with vehicle, approximately
eight to 18 counts of either activity. Desipramine pro-
duced a significant, dose-dependent decrease in immobi-
lity (F3,28=3.97; p=0.02) and produced a trend to increase
climbing (F3,28=2.87; p=0.06) (Fig. 2a). Desipramine had
no effect on swimming at any dose tested. Fluoxetine sig-
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nificantly decreased immobility (F3,23=4.84; p=0.01) at
3 mg/kg (p<0.05) and at 10 mg/kg (p<0.01), and produced
a nonsignificant increase in swimming at the highest dose
(Fig. 2b). However, fluoxetine did not significantly or dose-
dependently alter climbing.
In the forced swim test, the CRF antagonists antalarmin,
CP154,526, and R121919 did not alter immobility, swim-
ming, or climbing at any dose tested (Fig. 2c, e, f, respec-
tively). However, the CRF antagonist LWH234 produced a
significant decrease in immobility (F3,27=6.65; p=0.002) at
30 mg/kg (p<0.01) and an increase in climbing (F3,23=4.20;
p=0.02) at 30 mg/kg (p<0.05), but did not alter swimming
(Fig. 2d).
ACTH measurements Blood samples collected from tail
cuts before and after each swim period were assayed for
ACTH. Although tail sampling might be stressful for the
rats, the effects on ACTHwere minimal as demonstrated by
the low levels of baseline ACTH and ACTHmeasure in the
vehicle groups. On day 1 swim (habituation) prior to any
drug treatments, all rat groups had similar baseline and
swim stress-induced levels of ACTH (Fig. 3). Prior to
swimming, ACTH levels were ∼50 pg/ml or below for all
treatment groups. Fifteen minutes of swim exposure in-
creased ACTH levels to 200–340 pg/ml, a four- to seven-
fold increase above basal measurements. Between day 1
and day 2 swim, rats received three injections of either
vehicle or drug at 23.5, 5, and 1 h before day 2 swim test.
One hour after the final injection of vehicle or drug and
immediately prior to day 2 swim (test session), all treatment
groups had ACTH levels between 15 and 67 pg/ml, similar
to levels measured before day 1 swim.
After the 5-min test swim, ACTH levels in rats that
received vehicle injections were relatively similar to day 1
post swim levels of ACTH (Fig. 3). Subchronic adminis-
tration of desipramine significantly decreased swim-in-
duced increases in ACTH (F3,23=3.23; p=0.04) (Fig. 3a).
Although post hoc analysis did not identify a dose that
produced a significant decrease, 3 and 10 mg/kg desipra-
mine appeared to have the greatest effect on decreasing
Fig. 2 The effects of desipra-
mine (a), fluoxetine (b), anta-
larmin (c), LWH234 (d),
CP154,526 (e), and R121919 (e)
in the forced swim test in rats.
Rats were administered sub-
chronic injections of vehicle or a
single dose of either drug 23.5,
5, and 1 h prior to day 2 swim
test (N=6–8 per dose). The bars
and vertical lines above each
bar represent the mean and
standard error of the mean
(SEM) for immobility (open
bars), swimming (single-




ACTH levels. Fluoxetine did not alter ACTH levels mea-
sured following the day 2 test swim (Fig. 3b).
After subchronic treatment, antalarmin produced a non-
significant and nonconsistent reduction in ACTH; however,
there was a large degree of variability (Fig. 3c). Similarly,
CP154,526 slightly reduced ACTH at all doses tested;
however, the effect was not statistically significant (Fig. 3e).
R121919 significantly decreased swim-induced increases
in ACTH levels (F3,23=17.98; p<0.0001) at 10 and 30 mg/
kg (p<0.01 for both doses) (Fig. 3f). In contrast, the CRF
antagonist LWH234 did not reduce swim-induced ele-
vations in ACTH to any extent following day 2 swim
(Fig. 3d).
Restraint experiment The effects of LWH234 on restraint-
induced increases in ACTH were also measured to evaluate
this compound following exposure to different stressors.
Baseline ACTH levels prior to restraint were relatively low,
about 50 pg/ml or lower (Fig. 4). Restraint alone increased
ACTH levels to ∼250 pg/ml, a fivefold increase over base-
line values. With a 10-mg/kg LWH234 pretreatment, re-
straint produced a modest increase in ACTH to 115 pg/ml,
on average. At 30 mg/kg, LWH234 produced a complete
blockade of restraint-induced increases in ACTH.
Discussion
As previously described, CRF antagonists demonstrated
antidepressant-like effects in several behavioral assays. In
the current study, a number of CRF antagonists were com-
pared with known antidepressants in the same behavioral
procedure while we measured the effects of these com-
pounds on the HPA axis. In summary, the two known antide-
pressants, desipramine and fluoxetine, decreased immobility
in the forced swim test, indicating an antidepressant-like
effect. Interestingly, desipramine, but not fluoxetine, lowered
the swim-induced increase in ACTH. These results support
Fig. 3 The effects of desipra-
mine (DMI) (a), and fluoxetine
(FLX) (b), antalarmin (c),
LWH234 (LWH) (d),
CP154,526 (CP) (e), and
R121919 (R12) (f) on swim-
induced increase in ACTH.
Blood samples were taken be-
fore (pre d1) and after (post d1)
day 1 swim and before (pre d2)
and after (post d2) day 2 swim.
**p<0.01
219
previous findings that antidepressant treatments can alter
HPA activity, which may contribute to their antidepressant
effects. However, as demonstrated with fluoxetine, antide-
pressant activity can also be observed without changes in
HPA axis reactivity.
The CRF-R1 antagonists, antalarmin and CP154-526,
were previously shown to block stress-induced increases in
ACTH. In the current study, these two compounds produced
minor, nonsignificant decreases in ACTH. Alternatively,
the CRF-R1 antagonist, R121919, produced profound
reductions in swim-induced increases in ACTH. Although
these compounds had varying degrees of effect on the HPA
axis, none of these compounds produced antidepressant-
like effects in the forced swim test. One explanation for
these finding is that these compounds suppressed ACTH
release at the levels of the pituitary, but did not enter the
CNS and, therefore, did not produce centrally mediated
antidepressant activity in the forced swim test. Similarly,
previous studies demonstrated that peripheral blockade of
the HPA axis with dexamethasone did not alter behavioral
effects produced by central administration of CRF (Britton
et al. 1986a,b). However, this theory seems unlikely as it
was previously demonstrated that orally administered
R121919 occupied brain CRF1 receptors (Heinrichs et al.
2002) and decreased anxiety responses in rats (Gutman
et al. 2003) and that CP154,526 and antalarmin had
antidepressant-like effects in other animal models of de-
pression, suggesting that these compounds enter the CNS to
produce these centrally mediated behavioral effects. There-
fore, it was expected that these compounds crossed the
blood–brain barrier, but failed to produce antidepressant-
like activity in the current study.
It is possible that antalarmin, CP154,526, and R121919
did not decrease immobility in the forced swim test in the
current experiment because these compounds have some
immobilizing or behavior-suppressing effects in rats. This
behavioral suppression might have masked the antidepres-
sant-like effect, thus producing a false negative result.
However, based on observations in the present study, the
behavioral suppression produced by these compounds im-
mediately after injection dissipated prior to testing in the
forced swim test. Likewise, an increase in immobility
was not observed with these compounds as is frequently
observed with immobilizing or anxiogenic compounds
(Skrebuhhova et al. 1999).
Overall, these present results suggest that blocking
stress-induced increases in ACTH alone does not produce
antidepressant-like effects in the forced swim test. It is
interesting to note that none of the CRF antagonists com-
pletely blocked swim-induced increases in ACTH, such that
ACTH levels never returned to baseline values after CRF
antagonist treatment. Similarly, a previous study demon-
strated that the synthetic glucocorticoid, dexamethasone,
failed to completely suppress swim-stress-induced ACTH
increases (Jiang et al. 2004). These findings suggest that
other factors or stress-related neuropeptides may be con-
tinuing to increase ACTH during swimming. In addition,
the failure to completely block swim-induced increases in
ACTH may contribute to the lack of effect observed in the
forced swim test. However, these findings do not negate the
fact that changes in HPA activity may contribute to or
participate in the actions of some antidepressants, as ob-
served with desipramine.
Other research also demonstrated that blocking the HPA
axis alone might not be sufficient to produce antidepressant
activity in animal models. For example, chronic infusion of
CRF-R1 antisense did not alter immobility in the forced
swim test, suggesting that the CRF-R1 receptor may not
play a role in depressive mood states (Liebsch et al. 1999).
In contrast to the expectation that blocking stress hormones
might have antidepressant properties, intracerebroventric-
ular administration of CRF decreased immobility in the
forced swim test in rats, indicating antidepressant-like ac-
tivity (Garcia-Lecumberri andAmbrosio 2000). In addition,
administration of ACTH fragments enhanced the thera-
peutic effects of antidepressants in the forced swim test
(Zebrowska-Lupina et al. 1997). These findings suggest
that the involvement of stress hormones in antidepressant
activity in animal models might be more complex than
originally proposed. In addition, CRF antagonists were
demonstrated to produce inconsistent antidepressant effects
across animal models. For example, the CRF-R1 receptor
antagonist R278995/CRA0450 produced antidepressant-
like effects in some behavioral assays (learned helplessness
and olfactory bulbectomy), but not in others (mouse tail
suspension and the forced swim test) (Chaki et al. 2004).
Nielsen et al. (2004) made similar observations in mice to
those reported in this work. They found that R121919,
but not antalarmin, decreased immobility in the mouse tail
suspension test; however, none of the CRF antagonists
tested demonstrated antidepressant activity in the mouse
forced swim test. It seems unlikely that the lack of con-
sistency across behavioral assays will be resolved in the
near future; too many methodological possibilities exist
among studies.
Fig. 4 The effects of LWH234 on restraint-induced increases in
ACTH. Baseline bloods were collected before drug injection, and
LWH234 was injected 60 min prior to restraint initiation. Blood
samples were collected immediately after restraint (15 min) and 30,
60, and 90 min following restraint termination
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It has also been suggested that changes in the HPA axis
(ACTH measurements in blood plasma) may not be rep-
resentative of central CRF systems involved in affective
regulation (Heinrichs and Koob 2004). Thus, the com-
pounds tested in the current studymay have different effects
on the HPA axis as compared to central CRF systems.
Although this is a fascinating hypothesis, it presents a new
challenge of demonstrating that compounds are actually
acting on central CRF systems. All of these findings suggest
that the role of the HPA axis or CRF in depression as well as
its role in therapeutic treatments for depression is very
complicated and not well understood.
In the present study, the CRF antagonist LWH234 pro-
duced antidepressant-like effects in the forced swim test
without reducing swim-induced increases inACTH.LWH234
was also the only CRF antagonist tested that did not de-
crease swim-induced increases in ACTH to any extent;
however, this compound did block restraint induced in-
creases in ACTH. Although restraint and swimming pro-
duced similar elevations in ACTH, LWH234 reduced only
restraint-induced increases in ACTH. Therefore, these re-
sults suggest that the antidepressant action of LWH234 in
the forced swim test was independent of its effect on the
HPA axis, but may be produced by central CRF systems or
other neurotransmitter systems. These data also indicate
that CRF antagonist-induced endocrinological or behavior-
al changes may be dependent on the drug or stress paradigm
used.
In addition to the effects of CRF on stress-induced be-
havioral and endocrinological changes, other neuropeptides
released in response to stress may play a role in these mea-
surements. For example, arginine vasopressin (AVP) and
CRF are coreleased into portal circulation following stress
exposure and have synergistic effects on ACTH secretion.
The release of these peptides was reported to be differently
regulated by different stressors (Plotsky 1987). Likewise,
forced swim stress differentially altered CRF and AVP
transcription (Jiang et al. 2004), and the ACTH response in
AVP-deficient rats as compared to control rats was not
altered by hypertonic saline stress, but was diminished after
the 10-min swim stress (Makara et al. 2004). Interestingly,
vasopressin was proposed as a potential target of antide-
pressant therapy, and vasopressin antagonists were shown
to have antidepressant activity in preclinical models (for
review, see Scott and Dinan, 2002; Griebel et al. 2002a,b;
Alonso et al. 2004). Therefore, some of the CRF antag-
onists, such as LWH234, evaluated in the present may have
different effects on ACTH release or the synergistic actions
of CRF and AVP depending on the type of stressor used.
Based on the current data, the effects of LWH234 on stress
hormones, in general, obviously differed from the effects of
antalarmin, CP154,526, and R121919. For future studies,
coadministration of a CRF and AVP antagonist may pro-
duce antidepressant effects under the current experimental
design.
Previous research has also demonstrated that CRF antag-
onists have different effects depending on the type of
measure evaluated. For example, CRF antagonists astres-
sin, D-PheCRF12–41, and α-helical CRF9–41 altered some
CRF-induced behavioral and physiological effects, but not
others (Jones et al. 1999; Spina et al. 2000). In one study,
astressin, D-PheCRF12–41, and α-helical CRF9–41 blocked
the effects of CRF (i.c.v.) on food intake, but only astressin
and α-helical CRF9–41 blocked CRF-induced locomotor
activity (Jones et al. 1999). In contrast, Spina et al. (2000)
demonstrated that D-PheCRF12–41 and α-helical CRF9–41,
but not astressin, blocked CRF-induced locomotor activity.
Similarly, the CRF-R1 antagonist antalarmin produced
behavioral effects (induction and expression of conditioned
fear) without altering the stress-induced ACTH and corti-
costerone responses (Deak et al. 1999). In monkeys, as-
tressin B antagonized the effects of CRF on ACTH and
cortisol, but antalarmin blocked only CRF-induced ACTH
release (Broadbear et al. 2004). These data present an
interesting hypothesis that CRF-R1 receptor antagonists
may have unique profiles of action depending on the be-
havior or measure being studied.
Another explanation for the lack of effect of these CRF
antagonists in the current forced swim test experiments was
that the compounds were administered to relatively “nor-
mal” rats. Potential antidepressant activity of CRF antago-
nists may be best evaluated in subjects with altered HPA
axis responsivity. Studies have found that prior exposure
to stress or that genetic differences can greatly alter the
behavioral profiles of antidepressant drugs and of CRF
antagonists in animal models of depression (Borsini et al.
1989; Overstreet and Rezvani 1996; López-Rubalcava and
Lucki 2000; Overstreet et al. 2004). In the forced swim
test, initial exposure to the swim tank on day 1 supposedly
induces a state of “behavioral despair,” such that these
rats have altered emotional reactivity. The current data
might suggest that depressive behaviors that develop be-
tween day 1 and day 2 swim were not sufficient to observe
changes sensitive to CRF antagonist treatments; therefore,
other animal models than the forced swim test might be
required to evaluate the antidepressant properties of CRF
antagonists.
In conclusion, the CRF antagonists antalarmin,
CP154,526, and R121919 did not produce antidepres-
sant-like effects in the forced swim test although these
compounds reduced swim-induced elevations in ACTH to
different extents. The CRF antagonist LWH234 demon-
strated antidepressant-like effects without altering HPA
activity in the forced swim test. These data suggest that
reducing stress-induced increases in HPA activity alone
may not produce antidepressant-like activity; however, re-
ductions in HPA activity may contribute to antidepres-
sant actions of some treatments, as demonstrated with the
known antidepressant desipramine. In addition, these stud-
ies propose that CRF antagonists may have different
profiles of action endocrinologically and behaviorally de-
pending on the type of stressor or paradigm used. The
differences among stressors and the actions of CRF antag-
onists under various stress conditions should be studied in
order to better understand the HPA axis and the effects of
CRF antagonists.
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